Tanzeum "free" card

will fail with PF

 

To be a player all you need to be is profitable. Uf Tanzeum turns out to be a 300m per year drug, it's all good. Chicken little need to give it a rest for another 3 years.

 

3 weeks into launch and Trulicity doesn't even have 5 scripts in my district yet. 3 weeks into Tanzeum launch we had more than 20 scripts.

 

Looking good, teammates! Keep selling! You've got Novo on the run. See you next year, and stop being such crybabies!

http://www.firstwordpharma.com/node/1252386#axzz3MFO1pFUp

 

This troll knows nothing about Tanzeum. There is a significant advantage for patients. Cost, tolerability and access. It is very easy to sell, even though it is an injectable.

 

20 rxs in entire district of like 10 people. So 2 per team member? HAHAHA!

 

I think our real competition is Trulicity. Victoza is steadily declining in our market. Most of the new rx's going to the QW players.

 

Your biggest competition is our so called leadership. There is none! That is leadership.

 

To be a player in the diabetes market and the fact that we need this product to be a blockbuster, it needs to be a billion dollar a year drug. In order to keep the lights on we need to generate revenue. Lot's of good competition out there.

Patient first, taking tests, whatever! Business 101 says we need to sell products and do so profitably. Wall Street is watching.

 

This is the funniest thing I've ever read. "Our real competition"? You have to be in the game to be a competitor.

 

They are the varsity team and we are struggling to just make jv

 

You guys ever heard of Dulara? How about symbicort (5 years ago)? Those crappy meds started with nothing!! No superior efficacy or tolerability. No formulary coverage. Yet bot have been on the market for some time and ... have sales forces to promote the medication. Have you heard of symbicort lately? I'M sure you have. Tanzeum is going to be great! 500M per year should be easy. Chicken little, the sky is not falling! HA HA HA HA HA!!! We haven't evan seen the benefits of the recent national formulary additions. The drug has only been on the market four months. All is good!!

 

5 years from now, the CIA will be finished, and the sales force can start selling again

 

4 months in and our region has 400+ scripts each week and growing week on week. Some districts have over 700 scripts launch to date , most have 300+ scripts launch to date. Not exactly lighting the world on fire but showing that scripts can be generated. The free Tanzeum card is helping, but only slightly so far, but I anticipate that will improve as time goes on. Also not following the company strategy of getting endo business above all else, getting business where we can. This drug best suits primary care, as do all the GLP1s.

 

Your district should be gone with all due respect. If you don't have access and clearly your team has not been able to drive business then GSK should not have your district or call on the same customers you are assigned. Your districts team has demonstrated a lack of impact with these customers - it is not only your team but many across the country as well.

Some teams are performing - diagnosing why some districts perform differently than others is difficult but can be done - it is called making decisions based on sales performance - oh wait the Connelly model does not allow for this.

 

If you read the thread correctly the 20+ scripts were after 3 weeks, we now have several hundred scripts.

 

Oh boy and by selling again, you mean going back to breaking the law and putting children in harms way right?

 

What a juvenile stupid remark.

 

No the truth. Paxil for kids, Wellbutrin for Adhd in kids, imitrex pediatric migraine, advisor pimped to pediatrics too under12 years old. Just awful and evil. But hey this is GSK!

 

"all is good"? You can offer all the opinions you want. The drug is 30M behind plan after only 4 months. You are right the drugs you mentioned had SALES FORCES with launch and bonuses incentives. GSK has bonuses based on how well you study and take tests.

If you want another prediction based on better facts look at the two respiratory drug launch trajectories. They will give you a better indication of where this drug will be in a year..a lot further behind forecast unless the forecast is dropped considerably.